SynthesisBritish journal of cancer2013
Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis.
Synthesis in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Article
- SMARCB1 (INI-1)-deficient carcinoma with eosinophilia and cervical lymph node metastasis of unknown primary: a case report and literature review.Frontiers in oncology · 2026Article
- Cancer of unknown primary: the hunt for its elusive tissue-of-origin - is it time to call off the search?British journal of cancer · 2025Review
- Clinical outcome and genomic biomarkers of immune checkpoint inhibitor-based therapies for cancer of unknown primary: a multicenter, real-world study.Journal of cancer research and clinical oncology · 2025Article
- Diagnostic Challenges and Multidisciplinary Management of Invasive Mediastinal Adenocarcinoma: A Case Report.Cureus · 2025Article
- Article
- Metastatic squamous cell carcinoma of unknown primary: a case report and brief literature review.Frontiers in oncology · 2025Article
- Clinical outcomes of patients diagnosed with cancer of unknown primary or malignancy of undefined primary origin who were referred to a regional cancer center.International journal of clinical oncology · 2023Article
- [Cancer of unknown primary-The new ESMO guidelines].Radiologie (Heidelberg, Germany) · 2023Review
- Management and prognosis of patients with cancer of unknown primary: 20 years of experience.Turkish journal of medical sciences · 2023Article
- Cancer of Unknown Primary With Presumptive Pancreatic Cancer Treated With FOLFIRINOX.Journal of medical cases · 2021Article
- Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report.Annals of medicine and surgery (2012) · 2020Article
- Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?Frontiers in oncology · 2019Review
- Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site.Cancer immunology, immunotherapy : CII · 2016Article
- Molecular driver alterations and their clinical relevance in cancer of unknown primary site.Oncotarget · 2016Article
- Squamous cell carcinoma of unknown primary site presenting with an abdominal wall lesion as the primary symptom: A case report and review of the literature.Oncology letters · 2015Article
- Relapsed cervicomediastinal lymph node carcinoma with an unknown primary site treated with TS-1 alone: a case report.BMC research notes · 2013Article
- Cancer of unknown primary: a population-based analysis of temporal change and socioeconomic disparities.British journal of cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough chemotherapeutic regimens containing a taxane or platinum agent have been widely recommended for unfavourable carcinoma of unknown primary (CUP), no evidence exists for the superiority of any administered regimens. To date, the efficacy has been mostly assessed in the limited setting of phase II trials, and few attempts have been made to synthesise all available data for survival outcomes.
methodsElectronic databases were searched from 1980 to 2011. Survival results were combined for each pre-specified category of regimens using a random-effects model, and meta-regression models were used to adjust for heterogeneity in some known prognostic factors.
resultsA total of 32 studies were included for meta-analysis. Tendency towards better survival outcome by platinums or taxanes was indicated. After adjustment for important prognostic factors, however, the difference between the platinum-based and non-platinum regimens became no longer significant. Survival benefits by the taxane-based regimens remained significant, with a prolonged median survival time of 1.52 months (P=0.03) and a higher 1-year survival rate of 6.25% (P=0.05), but the benefit did not sustain for 2 years.
conclusionAlthough no effective therapies have been established, this meta-analysis helps to fill an important gap of evidence. However, caution should still be taken because of the potential unmeasured confounding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.